This week’s edition isn’t a payment rate or a billing code — it’s a proposed change to how federal research dollars get awarded in the first place, and it has the research community paying close attention.
Here’s what’s on the table, and what it could mean.
On May 29, the Office of Management and Budget published a proposed rule revising the Uniform Guidance — the framework governing how federal grants are awarded and administered across every agency. The proposal runs more than 400 pages and would convert long-standing guidance into binding regulation.
The most consequential provision: before a discretionary grant is awarded, a senior political appointee designated by the agency head would review it to confirm it is consistent with applicable law, agency priorities, and the national interest. Traditional scientific peer-review panels would continue to operate, but in an advisory capacity — meaning appointees would not be required to defer to their recommendations. The proposal also asks reviewers to weigh whether an award advances the administration’s stated policy priorities.
Several other provisions matter for research institutions. Agencies would gain authority to terminate existing awards that no longer serve agency priorities, with limited avenues for appeal. Grant funds generally could not be used for open-access publication fees unless required by statute. The rule adopts a “domestic-first” posture that would tighten review of international collaborations, and it codifies prior executive orders restricting diversity-related activities, with possible implications for health-disparities research.
Notably, the proposal does not cap indirect cost reimbursement rates — a step many had anticipated after last year’s contested attempt to limit them. Research and higher-education groups have flagged this as a meaningful point of relief.
OMB frames the changes as a way to improve transparency, accountability, and oversight of how federal funds are spent while reducing administrative burden on recipients. The comment period runs through July 13, and if finalized, the rule would take effect October 1.
## What it means for patients
The downstream connection here is the research pipeline. NIH alone funds tens of thousands of grants a year, much of it the basic science that eventually informs new treatments, clinical guidelines, and standards of care.
The open question is how an added review layer affects what reaches that pipeline. Supporters argue it ensures public dollars align with national priorities and improves accountability. Critics counter that inserting a political assessment ahead of scientific merit could shift funding away from areas that are scientifically promising but politically less visible. For patients, the effects would be indirect and slow to surface — felt in which lines of research advance and which do not, over a horizon of years rather than months.
## What it means for researchers and academic medical centers
For institutions that run labs and research hospitals, the practical concern is predictability. The current model assumes that rigorous work clearing peer review will, in most cases, be funded — and that funded multi-year programs are reasonably stable.
The proposal introduces new variables into that assumption: an appointee’s review on top of the panel’s, and broader agency discretion to terminate awards. Institutions will want to assess how that affects long-range planning — faculty recruitment, multi-year trials, and training commitments to early-career researchers — and how to manage the added uncertainty in their funding portfolios.
## What it means for the broader system
The larger context is the role of merit-based review in U.S. science. That system, largely insulated from year-to-year political shifts, is widely credited with U.S. leadership in biomedical research. The debate now is whether layering political review onto it strengthens accountability, as OMB argues, or weakens the independence that critics say underpins that leadership. Reasonable people in the policy and research communities are landing on different sides of that question, and the public comments will likely reflect that divide.
## My Take
This is a significant proposed change, and it deserves to be evaluated on its specifics rather than its headlines. The accountability rationale is real — there’s a legitimate argument that the public should have confidence that federal dollars are well spent. The substantive concern is also real: a review standard built around shifting policy priorities sits uneasily alongside a funding system designed to be insulated from exactly that.
The provisions worth watching most closely, in my view, are the termination authority and the limited appeal pathway, because predictability is what long-term research depends on most. How those clauses are interpreted will matter as much as the headline review requirement.
The important thing for readers to know is that this is a proposal, not a final rule. The comment period is open through July 13 via Regulations.gov, and stakeholders across the research and patient-advocacy communities are weighing in. If this is your field, it’s a week to read the text and consider commenting.
https://www.regulations.gov/commenton/OMB-2026-0034-0001
I’ll keep tracking where it goes.